C4 Therapeutics Inc (NAS:CCCC)
$ 4.115 -0.185 (-4.3%) Market Cap: 290.48 Mil Enterprise Value: 113.22 Mil PE Ratio: 0 PB Ratio: 1.20 GF Score: 60/100

C4 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 07:50PM GMT
Release Date Price: $37.97 (-3.99%)
Nader Sohraby;JPMorgan Securities LLC

Hello, everyone. I'm Nader Sohraby from the JPMorgan Healthcare Investment Banking team. On behalf of JPMorgan, it's my pleasure to introduce Andrew Hirsch, the President and CEO of C4 Therapeutics.

As a reminder, we'll try to reserve a few minutes at the end for Q&A. So if you have any questions, please submit them online using the ask-a-question feature at the bottom of the screen.

Thank you, and I'll now turn it over to Andrew.

Andrew Hirsch
C4 Therapeutics, Inc. - CEO, President & Director

Thank you, Nader, for the introduction. Good afternoon, and thank you for joining our presentation today.

Before I begin, I'd like to thank JPMorgan for inviting us to participate in the conference. I'm really pleased to provide an update on C4 Therapeutics today. I'm sure that most of you know the drill by now, but you should all have access to the slides. Iâll indicate which slide number I'm on as I move through the presentation. After the presentation, Stew Fisher, our CSO; Adam

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot